Posted 3rd February 2020 by Liv Sewell
Automation and digitisation are becoming increasingly important in the modern environment of bioprocesses 4.0. A new wave of biopharmaceutical manufacturing is already breaking. Driven by the PAT initiative and the goal of a well-understood and optimally controlled process, the digital transformation of bioprocesses is inevitable.
Posted 16th December 2019 by Liv Sewell
Ahead of the 3rd Global Bioprocessing, Bioanalytics and ATMP Manufacturing Congress in Dublin, we consider how Ireland is uniquely positioned to play a significant role in the next generation of biopharmaceutical manufacturing and delivery of life changing medicines.
Posted 8th July 2019 by Joshua Sewell
Following the Global Bioprocessing, Bioanalytics and ATMP Manufacturing Congress, we have made the following presentation slides from Jonathan Cartoux, Denis Decubber, Hani El-Sabbahy, Julia Leach & Corne Stroop.
Posted 3rd April 2019 by Joshua Sewell
Ireland is a place where innovation thrives and foreign direct investment finds a home. Thirty years ago, just 5,200 worked in an industry characterised by basic manufacturing. Now, the originator pharmaceutical companies directly employ 30,000 people, working on complex biologics manufacturing and the discovery of tomorrow’s cures.
Posted 17th September 2018 by Jane Williams
Drug discovery and development is a complex process that requires integration of multiple data points, experiments and calculated risk/benefit assumptions. It is therefore only natural that virtualization and big data analytics are a natural fit for implementations, expected to demonstrate significant cost-effective gains for the betterment of society, providing access to effective and safe medications.
Posted 8th January 2018 by Jane Williams
Antibody-drug conjugates (ADCs) combine the high specificity of a monoclonal antibody (mAb) for a target antigen with the highly potent cytotoxic activity of small-molecule drugs. Although the concept behind ADCs is relatively simple, the successful design and development of ADCs is a complex task. Similar to other biotherapeutics, the understanding of Pharmacokinetics (PK), Pharmacodynamics (PD), and Absorption, Distribution, Metabolism, and Excretion (ADME) properties of ADCs is critical for their successful development.